<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01781611</url>
  </required_header>
  <id_info>
    <org_study_id>IRB# 12-10</org_study_id>
    <nct_id>NCT01781611</nct_id>
  </id_info>
  <brief_title>Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)</brief_title>
  <acronym>DARE</acronym>
  <official_title>Dipyridamole Assessment for Flare Reduction in SLE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oklahoma Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oklahoma Medical Research Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dipyridamole, a medication extensively used in combination with aspirin for stroke&#xD;
      prevention, is a promising new treatment for lupus. Dipyridamole has been shown to inhibit&#xD;
      certain lymphocyte populations that are over-reactive in lupus and to delay the emergence of&#xD;
      lupus-related pathology in mice with lupus. The investigators are interested in investigating&#xD;
      the efficacy of dipyridamole in preventing flares in patients with lupus and its impact on&#xD;
      biomarkers of disease activity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      T cells in systemic lupus erythematosus (SLE) express an abnormal phenotype characterized by&#xD;
      increased effector functions and deficient regulatory responses. Dipyridamole, a&#xD;
      phosphodiesterase inhibitor extensively used in combination with low dose aspirin in&#xD;
      secondary stroke prevention, has been proposed as a specific T cell directed treatment for&#xD;
      SLE. Dipyridamole inhibits the calcium/calcineurin/NF-AT pathway in SLE T cells in vitro and&#xD;
      abrogates expression of cytokines and costimulatory molecules, eventually also affecting B&#xD;
      cell responses. Dipyridamole delays the emergence of lupus related pathology in lupus prone&#xD;
      mice, but has not yet been studied in humans with SLE. The investigators aim to investigate&#xD;
      the efficacy of dipyridamole in the prevention of flares in SLE patients after withdrawal of&#xD;
      background immunosuppressive medications. The investigators will additionally evaluate the&#xD;
      safety and tolerability of dipyridamole and its impact on quality of life measures in this&#xD;
      population. Furthermore, the effect of dipyridamole on T and B cell biomarkers will be&#xD;
      examined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">February 2013</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>British Isles Lupus Assessment Group Index-based Combined Lupus Assessment (BICLA)</measure>
    <time_frame>24 weeks</time_frame>
    <description>This is a landmark measure of percentage of patients who meet response criteria. To meet the BICLA response measure a patient must, compared to baseline, have a decrease in all moderate or severe scores on the British Isles Lupus Assessment Group (BILAG) index by at least one severity grade (Severe disease (BILAG A score) must drop to at least moderate (B or better) and B must drop to at least mild (C or not present). Also, there must be no increase in any other BILAG organ scores, no increase in The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, and no increase in the physician's global assessment (PGA) by more than 10% of the scale. Furthermore, there may no off protocol medication increases. Note on all scales mentioned a higher score signifies greater disease activity. Ranges on BILAG could be 0-108 but are rarely greater than 36. SLEDAI could range 0-105 but is rarely greater than 20. PGA 0-100 but rarely greater than 76.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic Lupus Erythematosus Responder Index (SRI) 4</measure>
    <time_frame>24 weeks</time_frame>
    <description>This is a landmark analysis of percentage of patients who meet the following response criteria: Compared to baseline there must be a 4 point decrease in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), no increase in The British Isles Lupus Assessment Group (BILAG) Index score and no more of an increase in Physician's Global Assessment (PGA) than 10% of the scale. As assessed here, there must also be no off protocol increase in medications. All scales signify worsening disease when scores increase. Ranges on BILAG could be 0-108 but are rarely greater than 36. SLEDAI could range 0-105 but is rarely greater than 20. PGA 0-100 but rarely greater than 76.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SRI Component Analyses: 4 Point Drop in SLEDAI</measure>
    <time_frame>24 weeks</time_frame>
    <description>This is a landmark analysis of percentage of patients who, compared to baseline, have a 4 point drop in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). A 4 point decrease signifies a clinically significant decrease in disease activity as reported in many studies and as commonly used as a clinical endpoint in trials. SLEDAI could range 0-105 but is rarely greater than 20.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>extended release dipyridamole/aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>extended release dipyridamole 200mg/aspirin 25mg twice daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>half a tablet of a 81mg aspirin twice daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>extended release dipyridamole 200mg/aspirin 25mg</intervention_name>
    <description>one tablet twice daily for 24 weeks</description>
    <arm_group_label>extended release dipyridamole/aspirin</arm_group_label>
    <other_name>Aggrenox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>81mg aspirin</intervention_name>
    <description>half a tablet twice daily for 24 weeks</description>
    <arm_group_label>aspirin</arm_group_label>
    <other_name>ASA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with SLE meeting the 1997 ACR Classification Criteria&#xD;
&#xD;
          -  Evidence of positive ANA or anti-dsDNA within one year of screening&#xD;
&#xD;
          -  SLEDAI ≥4 or ≥1 BILAG A or B at screening, despite standard of care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Leukopenia (WBC &lt;2.000/mm3) or lymphopenia (lymphocytes &lt; 300/mm3)&#xD;
&#xD;
          -  AST or ALT &gt;3 times above normal cut off values&#xD;
&#xD;
          -  Acute lupus nephritis defined as class II, IV or V nephritis diagnosed within 6 months&#xD;
             or prot/creat &gt; 1.5 gm/gm due to active lupus or in process of receiving induction&#xD;
             therapy for nephritis&#xD;
&#xD;
          -  Active CNS lupus affecting mental status&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Current requirement for anticoagulation&#xD;
&#xD;
          -  Contraindication to aspirin or dipyridamole, including history of recent or severe GI&#xD;
             bleeding, hemoglobin &lt;9 mg/dL, platelet count of &lt;30,000 /mm3 or unstable platelet&#xD;
             count&#xD;
&#xD;
          -  Any other medical condition, whether or not related to lupus which, in the opinion of&#xD;
             the investigator would render the patient inappropriate or too unstable to complete&#xD;
             the study protocol&#xD;
&#xD;
          -  Inability or unwillingness to understand and/or sign informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Thanou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oklahoma Medical Research Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oklahoma Medical Research Foundation</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kyttaris VC, Zhang Z, Kampagianni O, Tsokos GC. Calcium signaling in systemic lupus erythematosus T cells: a treatment target. Arthritis Rheum. 2011 Jul;63(7):2058-66. doi: 10.1002/art.30353.</citation>
    <PMID>21437870</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 2, 2013</study_first_submitted>
  <study_first_submitted_qc>January 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2013</study_first_posted>
  <results_first_submitted>October 9, 2020</results_first_submitted>
  <results_first_submitted_qc>November 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 25, 2020</results_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lupus</keyword>
  <keyword>dipyridamole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Dipyridamole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Those who wish access to this data may contact Joan Merrill at joan-merrill@omrf.org for further information</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>The data will be available on or before June 1 2021</ipd_time_frame>
    <ipd_access_criteria>For de-identified data only: Please submit a two page request describing the research you wish to do and the investigators credentials and current employment. This will be reviewed by our cohort advisory board and IRB prior to release.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 13, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT01781611/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All patients were recruited from the Oklahoma Medical Research Foundation clinic after a full informed consent process.</recruitment_details>
      <pre_assignment_details>There were no pre-assignment restrictions or procedures.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Extended Release Dipyridamole/Aspirin</title>
          <description>extended release dipyridamole 200mg/aspirin 25mg twice daily for 24 weeks&#xD;
extended release dipyridamole 200mg/aspirin 25mg: one tablet twice daily for 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Aspirin</title>
          <description>half a tablet of a 81mg aspirin twice daily for 24 weeks&#xD;
81mg aspirin: half a tablet twice daily for 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Extended Release Dipyridamole/Aspirin</title>
          <description>extended release dipyridamole 200mg/aspirin 25mg twice daily for 24 weeks&#xD;
extended release dipyridamole 200mg/aspirin 25mg: one tablet twice daily for 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Aspirin</title>
          <description>half a tablet of a 81mg aspirin twice daily for 24 weeks&#xD;
81mg aspirin: half a tablet twice daily for 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.5" spread="12.0"/>
                    <measurement group_id="B2" value="43.8" spread="12.9"/>
                    <measurement group_id="B3" value="44.3" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean BILAG Score at Entry</title>
          <description>The BILAG (Britiish Isles Lupus Assessment Group) index is commonly used in international SLE trials. It provides a discontinuous scale that assigns a score to each active organ system based on assessment of disease as mild (BILAG C) moderate (B) or severe (A). A global score is derived by assigning 12 points to each organ rated severe (A) 8 points for moderate (B) and 1 point for mild (C), adding these together. Thus, the total score is weighted by the severity of disease in each organ. Mean population scores at baseline are calculated for each group.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.2" spread="4.4"/>
                    <measurement group_id="B2" value="10" spread="4.9"/>
                    <measurement group_id="B3" value="10.9" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>British Isles Lupus Assessment Group Index-based Combined Lupus Assessment (BICLA)</title>
        <description>This is a landmark measure of percentage of patients who meet response criteria. To meet the BICLA response measure a patient must, compared to baseline, have a decrease in all moderate or severe scores on the British Isles Lupus Assessment Group (BILAG) index by at least one severity grade (Severe disease (BILAG A score) must drop to at least moderate (B or better) and B must drop to at least mild (C or not present). Also, there must be no increase in any other BILAG organ scores, no increase in The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, and no increase in the physician's global assessment (PGA) by more than 10% of the scale. Furthermore, there may no off protocol medication increases. Note on all scales mentioned a higher score signifies greater disease activity. Ranges on BILAG could be 0-108 but are rarely greater than 36. SLEDAI could range 0-105 but is rarely greater than 20. PGA 0-100 but rarely greater than 76.</description>
        <time_frame>24 weeks</time_frame>
        <population>Full Analysis Set was analyzed including all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Extended Release Dipyridamole/Aspirin</title>
            <description>extended release dipyridamole 200mg/aspirin 25mg twice daily for 24 weeks&#xD;
extended release dipyridamole 200mg/aspirin 25mg: one tablet twice daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>half a tablet of a 81mg aspirin twice daily for 24 weeks&#xD;
81mg aspirin: half a tablet twice daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>British Isles Lupus Assessment Group Index-based Combined Lupus Assessment (BICLA)</title>
          <description>This is a landmark measure of percentage of patients who meet response criteria. To meet the BICLA response measure a patient must, compared to baseline, have a decrease in all moderate or severe scores on the British Isles Lupus Assessment Group (BILAG) index by at least one severity grade (Severe disease (BILAG A score) must drop to at least moderate (B or better) and B must drop to at least mild (C or not present). Also, there must be no increase in any other BILAG organ scores, no increase in The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, and no increase in the physician's global assessment (PGA) by more than 10% of the scale. Furthermore, there may no off protocol medication increases. Note on all scales mentioned a higher score signifies greater disease activity. Ranges on BILAG could be 0-108 but are rarely greater than 36. SLEDAI could range 0-105 but is rarely greater than 20. PGA 0-100 but rarely greater than 76.</description>
          <population>Full Analysis Set was analyzed including all randomized patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Lupus Erythematosus Responder Index (SRI) 4</title>
        <description>This is a landmark analysis of percentage of patients who meet the following response criteria: Compared to baseline there must be a 4 point decrease in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), no increase in The British Isles Lupus Assessment Group (BILAG) Index score and no more of an increase in Physician's Global Assessment (PGA) than 10% of the scale. As assessed here, there must also be no off protocol increase in medications. All scales signify worsening disease when scores increase. Ranges on BILAG could be 0-108 but are rarely greater than 36. SLEDAI could range 0-105 but is rarely greater than 20. PGA 0-100 but rarely greater than 76.</description>
        <time_frame>24 weeks</time_frame>
        <population>Full analysis set of all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Extended Release Dipyridamole/Aspirin</title>
            <description>extended release dipyridamole 200mg/aspirin 25mg twice daily for 24 weeks&#xD;
extended release dipyridamole 200mg/aspirin 25mg: one tablet twice daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>half a tablet of a 81mg aspirin twice daily for 24 weeks&#xD;
81mg aspirin: half a tablet twice daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Lupus Erythematosus Responder Index (SRI) 4</title>
          <description>This is a landmark analysis of percentage of patients who meet the following response criteria: Compared to baseline there must be a 4 point decrease in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), no increase in The British Isles Lupus Assessment Group (BILAG) Index score and no more of an increase in Physician's Global Assessment (PGA) than 10% of the scale. As assessed here, there must also be no off protocol increase in medications. All scales signify worsening disease when scores increase. Ranges on BILAG could be 0-108 but are rarely greater than 36. SLEDAI could range 0-105 but is rarely greater than 20. PGA 0-100 but rarely greater than 76.</description>
          <population>Full analysis set of all randomized patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SRI Component Analyses: 4 Point Drop in SLEDAI</title>
        <description>This is a landmark analysis of percentage of patients who, compared to baseline, have a 4 point drop in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). A 4 point decrease signifies a clinically significant decrease in disease activity as reported in many studies and as commonly used as a clinical endpoint in trials. SLEDAI could range 0-105 but is rarely greater than 20.</description>
        <time_frame>24 weeks</time_frame>
        <population>Full Analysis Set of all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Extended Release Dipyridamole/Aspirin</title>
            <description>extended release dipyridamole 200mg/aspirin 25mg twice daily for 24 weeks&#xD;
extended release dipyridamole 200mg/aspirin 25mg: one tablet twice daily for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>half a tablet of a 81mg aspirin twice daily for 24 weeks&#xD;
81mg aspirin: half a tablet twice daily for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>SRI Component Analyses: 4 Point Drop in SLEDAI</title>
          <description>This is a landmark analysis of percentage of patients who, compared to baseline, have a 4 point drop in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). A 4 point decrease signifies a clinically significant decrease in disease activity as reported in many studies and as commonly used as a clinical endpoint in trials. SLEDAI could range 0-105 but is rarely greater than 20.</description>
          <population>Full Analysis Set of all randomized patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>All adverse events were recorded in the medical record and compiled for analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Extended Release Dipyridamole/Aspirin</title>
          <description>extended release dipyridamole 200mg/aspirin 25mg twice daily for 24 weeks&#xD;
extended release dipyridamole 200mg/aspirin 25mg: one tablet twice daily for 24 weeks</description>
        </group>
        <group group_id="E2">
          <title>Aspirin</title>
          <description>half a tablet of a 81mg aspirin twice daily for 24 weeks&#xD;
81mg aspirin: half a tablet twice daily for 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <description>This patient had sudden schedule change for non-emergent hysterectomy during the trial. Intubation was complicated by pneumonia but that did not prolong hospitalization (reported as non serious AE).</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>weight loss</sub_title>
                <description>This was not associated with anorexia reported by patient but no cause found. It continued for a number of weeks but did was not reported to continue after that</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>urticaria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Chlamydia infectoin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Spider Bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Muscle Cramp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>sprained ankle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Described as several dizzy spells with two episodes of near fainting or fainting</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sleep Disorder</sub_title>
                <description>At two different points in the study patient experienced insomnia and hypersomulence</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder Outlet Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joan T. Merrill, M.D.</name_or_title>
      <organization>Oklahoma Medical Research Foundation</organization>
      <phone>405-822-2336</phone>
      <email>joan-merrill@omrf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

